Plasmid DNA- and messenger RNA-based anti-cancer vaccination

Immunology Letters

Volumn 115, Issue 1, 2008, Pages 33-42

  Weide, Benjamin ^a   Garbe, Claus ^a   Rammensee, Hans Georg ^a   Pascolo, Steve ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer vaccination; Cancer vaccine; DNA vaccination; Minimal nucleic acid vectors; mRNA vaccine; pDNA vaccine; RNA vaccination

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; HEPATITIS B SURFACE ANTIGEN; MESSENGER RNA; MESSENGER RNA VACCINE; NUCLEIC ACID; PLASMID DNA; PLASMID DNA VACCINE; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG UTILIZATION; HUMAN; MELANOMA; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DNA, NEOPLASM; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; PLASMIDS; RNA, MESSENGER; VACCINATION; VACCINES, DNA;

EID: 37349109250     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.09.012     Document Type: Review

References (81)

1. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 247 (1990) 1465-1468
2. Probst J., Weide B., Scheel B., Pichler B.J., Hoerr I., Rammensee H.G., et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther 14 (2007) 1175-1180
3. Nishikawa M., and Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 25 (2002) 275-283
4. Pascolo S. Messenger RNA-based vaccines. Exp Opin Biol Ther 4 (2004) 1285-1294
5. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
6. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9 (2003) 1284-1290
7. Liao J.C., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6 (2006) 8
8. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
9. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92 (1995) 11810-11813
10. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94 (1997) 1914-1918
11. Griffioen M., Borghi M., Schrier P.I., and Osanto S. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int J Cancer 93 (2001) 549-555
12. Nishikawa H., Jager E., Ritter G., Old L.J., and Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 106 (2005) 1008-1011
13. Boasberg P.D., Hoon D.S., Piro L.D., Martin M.A., Fujimoto A., Kristedja T.S., et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 126 (2006) 2658-2663
14. Scanlan M.J., Simpson A.J., and Old L.J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4 (2004) 1
15. Gilboa E. The makings of a tumor rejection antigen. Immunity 11 (1999) 263-270
16. Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102 (2005) 16013-16018
17. Parmiani G., De Filippo A., Novellino L., and Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178 (2007) 1975-1979
18. Vonderheide R.H., Hahn W.C., Schultze J.L., and Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (1999) 673-679
19. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 33 (1997) 787-791
20. Fullen D.R., Zhu W., Thomas D., and Su L.D. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue. J Cutan Pathol 32 (2005) 680-684
21. Su Z., Dannull J., Yang B.K., Dahm P., Coleman D., Yancey D., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174 (2005) 3798-3807
22. Purbhoo M.A., Li Y., Sutton D.H., Brewer J.E., Gostick E., Bossi G., et al. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther 6 (2007) 2081-2091
23. Wolff J.A., and Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 54 (2005) 3-20
24. Maloy K.J., Erdmann I., Basch V., Sierro S., Kramps T.A., Zinkernagel R.M., et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 98 (2001) 3299-3303
25. Ledwith B.J., Manam S., Troilo P.J., Barnum A.B., Pauley C.J., Griffiths T.G., et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 43 (2000) 258-272
26. Probst J., Brechtel S., Scheel B., Hoerr I., Jung G., Rammensee H.G., et al. Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther 4 (2006) 4
27. Martinon F., Krishnan S., Lenzen G., Magne R., Gomard E., Guillet J.G., et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23 (1993) 1719-1722
28. Hess P.R., Boczkowski D., Nair S.K., Snyder D., and Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 55 (2006) 672-683
29. Perrie Y., Frederik P.M., and Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19 (2001) 3301-3310
30. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 75 (2001) 9037-9043
31. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C., Greenberg H.B., et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72 (1998) 5757-5761
32. Herrmann J.E., Chen S.C., Jones D.H., Tinsley-Bown A., Fynan E.F., Greenberg H.B., et al. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 259 (1999) 148-153
33. Singh M., Vajdy M., Gardner J., Briones M., and O'Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 20 (2001) 594-602
34. Sharpe S., Hanke T., Tinsley-Bown A., Dennis M., Dowall S., McMichael A., et al. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 313 (2003) 13-21
35. Prud'homme G.J., Glinka Y., Khan A.S., and Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 6 (2006) 243-273
36. Smorlesi A., Papalini F., Amici A., Orlando F., Pierpaoli S., Mancini C., et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24 (2006) 1766-1775
37. Boczkowski D., Nair S.K., Snyder D., and Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184 (1996) 465-472
38. Sudowe S., Ludwig-Portugall I., Montermann E., Ross R., and Reske-Kunz A.B. Prophylactic and therapeutic intervention in IgE responses by biolistic DNA vaccination primarily targeting dendritic cells. J Allergy Clin Immunol 117 (2006) 196-203
39. Stepinski J., Waddell C., Stolarski R., Darzynkiewicz E., and Rhoads R.E. Synthesis and properties of mRNAs containing the novel "anti-reverse" Cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG. RNA 7 (2001) 1486-1495
40. Holtkamp S., Kreiter S., Selmi A., Simon P., Koslowski M., Huber C., et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108 (2006) 4009-4017
41. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1 (1994) 751-761
42. Lollini P.L., De Giovanni C., Pannellini T., Cavallo F., Forni G., and Nanni P. Cancer immunoprevention. Future Oncol 1 (2005) 57-66
43. Conry R.M., Curiel D.T., Strong T.V., Moore S.E., Allen K.O., Barlow D.L., et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 8 (2002) 2782-2787
44. Rosenberg S.A., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14 (2003) 709-714
45. Cassaday R.D., Sondel P.M., King D.M., Macklin M.D., Gan J., Warner T.F., et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 13 (2007) 540-549
46. Tagawa S.T., Lee P., Snively J., Boswell W., Ounpraseuth S., Lee S., et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 98 (2003) 144-154
47. Timmerman J.M., Singh G., Hermanson G., Hobart P., Czerwinski D.K., Taidi B., et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62 (2002) 5845-5852
48. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91 (2004) 688-694
49. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 8 (2002) 1028-1037
50. Sheets E.E., Urban R.G., Crum C.P., Hedley M.L., Politch J.A., Gold M.A., et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188 (2003) 916-926
51. Shaw D.R., and Strong T.V. DNA vaccines for cancer. Front Biosci 11 (2006) 1189-1198
52. Rains N., Cannan R.J., Chen W., and Stubbs R.S. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 48 (2001) 347-351
53. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109 (2002) 409-417
54. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63 (2003) 2127-2133
55. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
56. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother, in press.
57. Van den Eynde B.J., and van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 9 (1997) 684-693
58. Tureci O., Chen Y.T., Sahin U., Gure A.O., Zwick C., Villena C., et al. Expression of SSX genes in human tumors. Int J Cancer 77 (1998) 19-23
59. Chen Y.T., Gure A.O., Tsang S., Stockert E., Jager E., Knuth A., et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95 (1998) 6919-6923
60. Tureci O., Sahin U., Koslowski M., Buss B., Bell C., Ballweber P., et al. A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene 21 (2002) 3879-3888
61. Wang Y., Han K.J., Pang X.W., Vaughan H.A., Qu W., Dong X.Y., et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169 (2002) 1102-1109
62. Koslowski M., Tureci O., Bell C., Krause P., Lehr H.A., Brunner J., et al. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res 62 (2002) 6750-6755
63. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 38 (2000) 208-217
64. Gribben J.G., Ryan D.P., Boyajian R., Urban R.G., Hedley M.L., Beach K., et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11 (2005) 4430-4436
65. Todorova K., Ignatova I., Tchakarov S., Altankova I., Zoubak S., Kyurkchiev S., et al. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 5 (2005) 1
66. Triozzi P.L., Aldrich W., Allen K.O., Carlisle R.R., LoBuglio A.F., and Conry R.M. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 28 (2005) 382-388
67. Nemunaitis J., Meyers T., Senzer N., Cunningham C., West H., Vallieres E., et al. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 13 (2006) 1185-1191
68. Nair S.K., Morse M., Boczkowski D., Cumming R.I., Vasovic L., Gilboa E., et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235 (2002) 540-549
69. Morse M.A., Nair S.K., Boczkowski D., Tyler D., Hurwitz H.I., Proia A., et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 32 (2002) 1-6
70. Morse M.A., Nair S.K., Mosca P.J., Hobeika A.C., Clay T.M., Deng Y., et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 21 (2003) 341-349
71. Caruso D.A., Orme L.M., Neale A.M., Radcliff F.J., Amor G.M., Maixner W., et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncol 6 (2004) 236-246
72. Mu L.J., Kyte J.A., Kvalheim G., Aamdal S., Dueland S., Hauser M., et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 93 (2005) 749-756
73. Caruso D.A., Orme L.M., Amor G.M., Neale A.M., Radcliff F.J., Downie P., et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 103 (2005) 1280-1291
74. Kyte J.A., Mu L., Aamdal S., Kvalheim G., Dueland S., Hauser M., et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13 (2006) 905-918
75. Carralot J.P., Weide B., Schoor O., Probst J., Scheel B., Teufel R., et al. Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet Vaccines Ther 3 (2005) 6
76. Scheel B., Aulwurm S., Probst J., Stitz L., Hoerr I., Rammensee H.G., et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 36 (2006) 2807-2816
77. Scheel B., Teufel R., Probst J., Carralot J.P., Geginat J., Radsak M., et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35 (2005) 1557-1566
78. Scheel B., Braedel S., Probst J., Carralot J.P., Wagner H., Schild H., et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 34 (2004) 537-547
79. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
80. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
81. Carralot J.P., Probst J., Hoerr I., Scheel B., Teufel R., Jung G., et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 61 (2004) 2418-2424